Released: 12/01/2010
Payment of Directors' Fees in Shares
12 January 2010, London, UK, and Cambridge, MA:Cancer drug developer Antisoma plc(LSE:
ASM; USOTC: ATSMY) today announces that three Non-Executive Directors of Antisoma have
taken all or part of their fees for the quarter ended 31 December 2009 in ordinary
shares pursuant to resolutions of the Board of Directors dated 14 September 2004 and
subsequently.
The new ordinary shares were issued at a price of 33 pence per share, this being the
mid-market closing price on the last trading day of the quarter (31 December 2009). The
relevant Directors have agreed not to dispose of the shares allotted for a minimum
period of one year.
The allotment and total holdings following this allotment are shown below.
Director Allotted Total Percentage of issued ordinary shares
12 Jan 10
holding
Michael Lewis 26,515 180,778 0.03%
Barry Price 17,945 811,022 0.13%
Birgit Stattin-Norinder 6,629 6,629 0.001%
6,629
0.001%
Application will be made to the London Stock Exchange and the UK Listing Authority for
the admission of the new ordinary shares of 1p each. The total number of ordinary shares
in the Company in issue and admitted to the Official List following the above allotments
will be 626,045,293.
The new ordinary shares will rank pari passu with the Company's existing ordinary
shares.
Enquiries:
Chris Elston
Antisoma plc
+44 (0)20 3249 2145
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel
products for the treatment of cancer. The Company has operations in the UK and the US.
Please visit www.antisoma.com for further information about Antisoma.
HUG#1372789